CJC-1295 No DAC & Ipamorelin Research: Adding to an Existing Stack

CJC-1295 no DAC and Ipamorelin appear together in research literature because they engage two separate receptor systems — one is a growth hormone–releasing hormone (GHRH) analog, the other a selective ghrelin-receptor (GHS-R1a) agonist. That separation is why laboratories already working with one commonly source the other, and why a catalog stocking only one of them tends to field repeat requests for the second. For a wholesale buyer, adding the second compound to a line already on the shelf is a procurement decision, not a scientific one: it turns on supplier consolidation, matched batch documentation, and whether both SKUs advance you through the same volume tier. Real Peptides supplies both as research-use-only compounds, tested to 99%+ HPLC purity with seven-panel batch testing and publicly verifiable certificates of analysis.

Two receptor pathways, one reason buyers stock both

CJC-1295 without DAC is built on the modified GRF(1-29) sequence — the fragment of GHRH that retains receptor-binding activity — with amino acid substitutions the literature describes as improving resistance to enzymatic degradation. The "no DAC" designation signals the absence of the drug affinity complex, the albumin-binding element carried by the DAC-modified version. Research characterizes the no-DAC form as comparatively short-acting as a result, which is precisely why investigators select it when pulsatile signaling is the variable under study.

Ipamorelin is a pentapeptide secretagogue acting at the GHS-R1a receptor. Studies report a selectivity profile that distinguishes it from earlier-generation secretagogues, which showed broader endocrine cross-activity in published work. Because the two compounds reach the same downstream axis through different receptor populations, combination designs are a routine feature of secretagogue research — investigators use them to isolate pathway-specific contributions rather than to produce a single pooled effect.

None of that is a claim about outcomes, and none of it belongs in customer-facing marketing. What it means commercially is narrow and reliable: demand for these two compounds is correlated. Buyers evaluating catalog depth should expect that stocking one without the other leaves a predictable gap, and should plan reorder cadence accordingly rather than treating the second SKU as a speculative addition.

What the second SKU actually changes on the purchasing side

The word "stack" carries two meanings in this market, and conflating them causes real problems. In a laboratory context it refers to combination study design. On the purchasing side — the only side a wholesale buyer controls — it means catalog depth: how many related SKUs you hold, from how many suppliers, under how many documentation standards.

That second definition is where the cost sits. Sourcing two related compounds from two different suppliers means two COA formats, two purity-reporting conventions, two lot-numbering schemes, two shipping origins, and two escalation paths when a customer asks a question about a specific batch. Reconciling that during an inventory review, or under time pressure when a lot is questioned, consumes hours that consolidation would have saved. Single-source sourcing for related compounds is not about loyalty; it is about having one documentation standard to defend.

Consolidation also changes order economics in ways that are structural rather than promotional. Pairing both SKUs on a single purchase order reduces the number of inbound shipments, smooths cash timing against shelf turn, and — in programs that aggregate volume across the catalog rather than counting each SKU separately — moves you through pricing tiers faster than two half-sized orders ever would.

The counterweight is shelf turn. Lyophilized material should be held under the storage conditions stated on the product documentation, and inventory that sits is inventory that ages. Order against observed demand, not against a tier you have no realistic path to selling through. Margins in this category vary widely with volume, compound, and how you position the line — no supplier can hand you a number that holds for your business.

How wholesale tiers and minimums actually work

Wholesale pricing in research peptides is almost always tiered by unit volume, but the mechanics underneath vary enough that two programs quoting similar headline pricing can produce very different landed costs. Before committing to a supplier, resolve these questions in writing:

• Is volume counted per SKU or aggregated across the catalog? Per-SKU counting penalizes buyers building breadth. Aggregated counting rewards exactly the move described here — adding a second related compound to an existing line.
• Does the tier reset each order, or hold across a period? A tier that resets on every purchase order forces larger single buys and worse cash timing.
• Is there a per-SKU minimum, a per-order minimum, or both? These are different constraints and suppliers do not always distinguish them clearly.
• Is pricing published or quote-only? Quote-only pricing is not automatically a red flag, but it makes modeling impossible and conceals where the tier steps actually fall. Published pricing lets you build a real purchasing plan before you ever speak to anyone.
• Is documentation included or billed separately? Some programs treat certificates of analysis as a paid add-on or an on-request favor. That structure should inform how you weigh the quote.
• What is the restock and backorder policy, and is lot continuity maintained? A supplier that silently substitutes lots between shipments makes your own batch traceability unreliable.

Comparing the two compounds at the catalog level

Due diligence before you add any supplier's SKU

The single most useful distinction in supplier evaluation is between per-batch testing and archival testing. A supplier that ran analysis once, years ago, and reuses that certificate across every subsequent lot is telling you nothing about the material in the box you received. Per-batch testing, with a lot number on the vial that matches a certificate you can independently pull, is the only version of this claim that carries weight.

The testing categories serious buyers ask about include purity by HPLC reported as percent area, identity confirmation by mass spectrometry, endotoxin and bioburden screening, heavy metals, residual solvents, and water content. You do not need to be an analytical chemist to evaluate these — you need to confirm that a panel exists, that it runs per lot, and that you can see the results without asking permission.

Run this on your current supplier before you run it on a prospective one. Buyers frequently discover that the line they already carry would not survive the scrutiny they are about to apply to a new one.

Compliance questions to take to your own counsel

This section is informational and is not legal advice. Research-use-only compounds sit in a regulatory space where the correct answer depends on your business model, your state, and how you represent the product — which means the questions below need to be answered by your attorney and, where applicable, your state licensing board, not by a supplier's blog post.

Ask your counsel how research-use-only labeling must be maintained through resale in your situation, and what representations in your own marketing would change that classification. Ask what registration, licensing, or facility requirements may attach to holding and reselling research materials in your state — requirements differ, and a general rule you read online will not reliably describe your obligations. Ask how recordkeeping and lot traceability should be structured so that you can respond to a customer inquiry about a specific batch. And ask what customer-verification steps, if any, your counsel recommends for your channel.

A supplier that answers these questions for you definitively should concern you more than one that declines. The honest position is that compliance is buyer-specific, and that your documentation trail is the asset that makes any of it defensible.

What Real Peptides does differently

Real Peptides tests to 99%+ HPLC purity and runs seven-panel batch testing on production lots. Certificates of analysis are publicly verifiable — a prospective partner can check the lab results directly, before applying, without requesting access or paying for a document. That is a deliberate inversion of the common industry pattern in which testing claims are asserted in marketing copy and the supporting paperwork is treated as a privilege.

Orders ship from US-based fulfillment within 5–7 days, which matters for a buyer managing shelf turn across a growing catalog rather than a single SKU. The Wholesale Partner Program uses a three-step application: submit business details, complete verification, and receive tier pricing.

All compounds are supplied strictly for laboratory research. Real Peptides does not provide dosing, preparation, or administration guidance of any kind, and does not describe research compounds as therapeutics.

Buyers evaluating the full line can review the CJC-1295 No DAC 10mg and Ipamorelin 10mg listings alongside related GHRH-analog research material such as Tesamorelin 10mg, or look at how these compounds sit within the broader Growth Factor & Tissue Signaling Research and Popular Peptides collections when planning catalog depth.

If your business is already moving one of these two compounds and you are sourcing the second, the practical next step is to compare your current supplier's batch documentation against what is publicly posted, then submit the three-step Wholesale Partner Program application to see tier pricing against your actual order volume.